ASCO 2024 | MANCAN2: managing hot flushes and night sweats in men with prostate cancer

Simon Crabb • 1 Jun 2024

ASCO 2024

MANCAN2

Simon Crabb, PhD, MBBS, University of Southampton, Southampton, UK, discusses the findings from the MANCAN2 trial, which evaluated the efficacy of cognitive-behavioral therapy (CBT) combined with treatment as usual (TAU) in reducing hot flushes and night sweats (HFNS) in patients with prostate cancer on androgen deprivation therapy (ADT). Existing nurses were trained to carry out CBT, which reduces the need to use more resources or hire new people. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria – AstraZeneca; Bristol Myers Squibb; Ipsen; Merck; Pfizer
Consulting or Advisory Role – Amgen; Amphista Therapeutics; AstraZeneca; Bayer; Janssen; Merck; MSD; Pfizer
Research Funding – Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Roche
Travel, Accommodations, Expenses – Bayer; Janssen; Merck